Eikon Therapeutics Inc. Common Stock

EIKN | NASDAQ

$5.31

-$0.04 (-0.75%)

At close: Oct 30, 2026, 4:00 PM ET

$5.20

-$0.11 (-2.07%)

Pre-market: Nov 2, 2026, 6:37 AM ET

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025
Net Income	-88.41M	-82.96M	-79.66M	-71.14M
Depreciation & Amortization	5.03M	5.11M	5.11M	6.3M
Stock-Based Compensation	n/a	n/a	3.86M	3.99M
Other Working Capital	14.07M	-19.23M	33.16M	2.35M
Other Non-Cash Items	3.86M	1.95M	-654K	-1.4M
Deferred Income Tax	n/a	n/a	n/a	n/a
Change in Working Capital	14.56M	-13.91M	29.62M	2.71M
Operating Cash Flow	-64.96M	-89.8M	-41.72M	-59.54M
Capital Expenditures	-251K	-262K	-66K	-2.6M
Cash Acquisitions	n/a	n/a	n/a	n/a
Purchase of Investments	-79.82M	-306.96M	-53.97M	-68.72M
Sales Maturities Of Investments	126.5M	104M	94.75M	99M
Other Investing Acitivies	n/a	n/a	n/a	n/a
Investing Cash Flow	46.43M	-203.22M	40.71M	27.68M
Debt Repayment	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a
Other Financial Acitivies	n/a	n/a	n/a	n/a
Financial Cash Flow	25K	349.31M	1.09M	211K
Net Cash Flow	-18.54M	56.25M	75K	-31.65M
Free Cash Flow	-65.21M	-90.06M	-41.79M	-62.14M
Adj. Free Cash Flow	-65.21M	-90.06M	-45.65M	-66.13M
Maintenance CapEx	-251K	-262K	-66K	-2.6M
Growth CapEx	n/a	n/a	n/a	n/a
Owner Earnings	-65.21M	-90.06M	-41.79M	-62.14M